Celltrion is strengthening its market presence across Asia by expanding prescriptions of key biosimilar products through its direct sales strategy.
The company said it has been securing tenders and implementing localized marketing strategies in major Asian markets including Malaysia, Singapore, Thailand, and Hong Kong. As a result, several of its biosimilar products are achieving leading market shares in these countries.
Strong performance has been particularly evident in the autoimmune disease treatment segment. Celltrion’s flagship biosimilar Remsima (infliximab) has maintained dominant prescription shares across the region. According to pharmaceutical market research firm IQVIA, Remsima held market shares of 93 percent in Singapore, 77 percent in Hong Kong, 73 percent in Thailand, and 65 percent in Malaysia as of the third quarter of 2025, ranking first in prescriptions in each market.
Celltrion’s local subsidiaries have strengthened their competitiveness in Asia’s tender-driven markets by emphasizing supply stability and consistent product delivery. The company has also participated actively in local academic conferences to increase product awareness among healthcare professionals while expanding its network with key opinion leaders to support prescription growth.
Another autoimmune treatment, Yuflyma (adalimumab), is also gaining traction in Asia following the success of Remsima. In Singapore, Yuflyma has surpassed the original drug to rank second in market share, showing continued prescription growth.
Celltrion’s Singapore subsidiary plans to strengthen its competitiveness in upcoming adalimumab tenders by launching an additional 20 mg formulation alongside the existing 40 mg version. The company has also introduced Yuflyma in Malaysia and Thailand and plans to expand prescriptions through tailored marketing strategies aligned with each market’s competitive environment.
Celltrion’s oncology biosimilars are also showing strong performance across Asia. Herzuma (trastuzumab), used to treat breast and gastric cancers, recorded market shares of 87 percent in Thailand, 57 percent in Hong Kong, and 51 percent in Malaysia as of the third quarter of 2025. Meanwhile, Truxima (rituximab), used to treat blood cancers, maintained the top prescription position with market shares of 90 percent in Singapore and 79 percent in Thailand.
In Thailand, Celltrion’s local subsidiary has built long-term partnerships with all university hospitals, gaining recognition for the quality of key products including Remsima, Truxima, and Herzuma. These three products are used exclusively in university hospitals, demonstrating strong prescription performance.
Despite intensified competition after Thailand introduced regulatory changes in 2023 allowing product approvals based solely on domestic clinical data, Celltrion has strengthened its market influence through product quality, supply reliability, and strong local sales and marketing capabilities.
Building on the success of its existing portfolio, Celltrion is continuing to launch new products across Asia. In Singapore, where eight autoimmune and oncology treatments are currently marketed, the company plans to further strengthen its portfolio by obtaining approval for the denosumab biosimilar Stoboclo-Osenvelt within the year.
Celltrion’s Thailand subsidiary also plans to introduce three additional biosimilars this year—Stekima (ustekinumab), Vegzelma (bevacizumab), and Omlyclo (omalizumab)—to expand its product lineup and enhance sales synergies.
A Celltrion official said the company is continuing to increase prescriptions in Asia’s tender-based markets by leveraging product competitiveness and supply stability, adding that it will further strengthen the performance of existing products while launching new ones to achieve early market penetration and improved profitability.
저작권자 © Korea IT Times 무단전재 및 재배포 금지
link